Nchi: Uingereza
Lugha: Kiingereza
Chanzo: MHRA (Medicines & Healthcare Products Regulatory Agency)
Doxepin hydrochloride
Morningside Healthcare Ltd
N06AA12
Doxepin hydrochloride
50mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030100; GTIN: 5055132717628
PACKAGE LEAFLET: INFORMATION FOR THE USER Doxepin 10 mg, 25 mg and 50 mg Capsules Doxepin hydrochloride Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Doxepin Capsules are and what they are used for 2. What you need to know before you take Doxepin Capsules 3. How to take Doxepin Capsules 4. Possible side effects 5. How to store Doxepin Capsules 6. Contents of the pack and other information 1. What Doxepin Capsules are and what they are used for The name of this medicine is Doxepin 10 mg, 25 mg and 50 mg Capsules. The active ingredient is doxepin hydrochloride. Doxepin is an antidepressant. It is one of a group called tricyclic antidepressants. Your doctor has decided that this medicine is suitable for treating your depression. Depression is a clinical illness. If you have been feeling sad, tearful or unable to enjoy life as you used to, Doxepin Capsules may help you to feel better. It may also help if you have difficulty sleeping because of your depression. If you are not sure why you are on these capsules, ask your doctor. 2. What you need to know before you take Doxepin Capsules Do not take Doxepin Capsules: • If you are allergic to tricyclic antidepressants, doxepin, or any of the other ingredients of this medicine (listed in section 6). • If you have serious liver problems. • If you have glaucoma (increased eye pressure). • If you suffer from difficulty in passing urine. • If you are breast-feeding. • If you are taking, or have taken in the last two weeks, any medicines Soma hati kamili
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Doxepin 50 mg Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains doxepin hydrochloride equivalent to 50 mg doxepin. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Blue opaque cap and body size ‘2’ hard gelatin capsule, printed with white ink ‘Doxepin’ on cap and ’50 mg’ on body. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptoms of depressive illness in adults, especially where sedation is required. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The optimum oral dose depends on the severity of the condition and the individual patient’s response. The dose required may vary from 25-300mg daily. Doses up to 100mg daily may be given on a divided or once daily schedule. Should doses over 100mg daily be required, they should be administered in three divided doses daily. 100mg is the maximum dose recommended at any one time. This dose may be given at bedtime. For the majority of patients with moderate or severe symptoms, it is recommended that treatment commences with an initial dose of 75mg daily. Many of these patients will respond satisfactorily at this dose level. For patients who do not, the dosage may be adjusted according to individual response. In more severely ill patients, it may be necessary to administer a dose of up to 300mg in divided doses daily, to obtain a clinical response. In patients where insomnia is a troublesome symptom, it is recommended that the total daily dose be divided so that a higher proportion is given for the evening dose; similarly, if drowsiness is experienced as a side effect of treatment, doxepin may be administered by this regimen or the dosage may be reduced. It is often possible, having once obtained a satisfactory therapeutic response, to reduce the dose for maintenance therapy. The optimal anti-depressant effect may not be evident for two to three weeks. _PAEDIATRIC POPULATION _ The safety and efficacy in children under 18 y Soma hati kamili